Search - tctmd.com

Displaying 61 - 80 of 175

Sort: Relevancy | Date

Presentation TCT 2019

The Case for Functional (Not Anatomic) Complete Revascularization: Preview of FAME 3

Presenter: William Fearon

September 27, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Conference News ACC 2019

High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI

Michael O'Riordan

March 21, 2019

News Conference News CRT 2019

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

Yael L. Maxwell

March 07, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

FARGO: FFR No Help for CABG in Patients With Multivessel Disease

L.A. McKeown

November 27, 2018

Presentation TCT 2018

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Presenter: David J. Cohen, Sunil V. Rao, Bernard J. Gersh

September 22, 2018

News Daily News

FFR Values Linked to Quality-of-Life Improvement After PCI in Stable CAD Patients

Todd Neale

September 21, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

Todd Neale

August 26, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

Presentation EuroPCR 2018

Five-year Outcomes with PCI Guided by Fractional Flow Reserve in Patients with Stable Coronary Artery Disease (FAME 2)

Presenter: Panagiotis Xaplanteris

May 23, 2018

News Conference News EuroPCR 2018

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

Caitlin E. Cox

May 22, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Shelley Wood

May 17, 2018

Presentation CIT 2018

The study is presented on behalf of the FAME 2 Investigators

Presenter: William F. Fearon

March 23, 2018

News Conference News ACC 2018

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

Caitlin E. Cox

March 10, 2018

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

Advertisement

The Case for Functional (Not Anatomic) Complete Revascularization: Preview of FAME 3

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

FARGO: FFR No Help for CABG in Patients With Multivessel Disease

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

FFR Values Linked to Quality-of-Life Improvement After PCI in Stable CAD Patients

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Five-year Outcomes with PCI Guided by Fractional Flow Reserve in Patients with Stable Coronary Artery Disease (FAME 2)

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

The study is presented on behalf of the FAME 2 Investigators

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content